Question

Which institute has approved the emergency use of 2-deoxy-D-Glucose as additive therapy for Covid -19 patients?

• A. Ministry of Health and Family welfare
• B. Indian Council of Medical Research
• C. Drug controller General of India
• D. World Health Organization

Answer 1

The Correct Option is C

The Drug Controller General of India is the regulatory body responsible for approving drugs, vaccines, and other medical interventions in India. In May 2021, the DCGI granted emergency use authorization for 2-deoxy-D-Glucose as an adjunct therapy in moderate to severe COVID-19 cases. This decision was based on the recommendations of the Indian Council of Medical Research (ICMR), which conducted clinical trials and found promising results for the use of 2-DG in COVID-19 treatment.
The other options, such as the Ministry of Health and Family Welfare, Indian Council of Medical Research (ICMR), and World Health Organization (WHO), play significant roles in healthcare and research but are not directly involved in the approval process for specific drugs at the national level in India.

Answer 2

Correct Answer: Drug Controller General of India 

Elaborate Explanation:
The Drug Controller General of India (DCGI) is the top authority in India that approves new medicines and vaccines for public use. In May 2021, DCGI approved the emergency use of a special drug called 2-deoxy-D-glucose (2-DG) to help in the treatment of COVID-19 patients.

This drug was developed by scientists at the Institute of Nuclear Medicine and Allied Sciences (INMAS), which is a part of DRDO (Defence Research and Development Organisation), in collaboration with a pharmaceutical company, Dr. Reddy’s Laboratories.

The trials showed that when 2-DG is used along with standard COVID-19 treatment:
• Patients recovered faster
• Their need for oxygen support reduced

That’s why DCGI gave permission to use this drug during emergencies like the COVID-19 pandemic. The other options in the question (like WHO, ICMR, and the Ministry of Health) are important health organizations, but only the DCGI has the legal authority to approve the use of new medicines in India.

In summary: DCGI approved the use of 2-DG as an additional treatment to improve the recovery of COVID-19 patients in India.